JC10 Rec'd PCT/PTQ 23 MAR 2005

Approved for use through 3/31/2007, OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER 2376.0010000/SRL/TAC

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) To be assigned \( \bigcap \)

INTERNATIONAL FILING DATE 23 September 2003 PRIORITY DATE CLARMED 24 September 2002

INTERNATIONAL APPLICATION NO. PCT/DE2003/ ,03165 TITLE OF INVENTION Inhibition Of Protein Kinase C Alpha For Treatment Of Diabetes Mellitus And Cardiovascular Diseases APPLICANT(S) FOR DO/EO/US Jan MENNE and Hermann HALLER Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. X This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. 14. X An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. 17. L A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). Other items or information: copy of International Search Report; and Copy of letter to WIPO requesting transfer of rights

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

## JC14 Rec'd PCT/PTO 23 MAR 2005

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007, OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)			) INTERNATIONAL AF	INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/528806			PCT/DE200	PCT/DE2003/ 03165		2376.0010000/SRL/TAC	
The following fees have been submitted					CALCULATIONS	PTO USE ONLY	
21. X Basic national fee\$300				\$ 300.00			
	ination fee		1				
If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)					\$		
All other situations\$200					200.00	<u> </u>	
23. 🗵 Search fee							
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority							
International Search Report prepared and provided to the Office					\$ 500.00		
All other situations\$500					500.00	<del> </del>	
TOTAL OF 21, 22 and 23 = Additional fee for specification and drawings filed in paper over 100 sheets (excluding					\$ 1.000.00	<del> </del>	
sequence listing or computer program listing filed in an electronic medium).							
The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets	Extra Sheets		n additional 50 or fraction up to a whole number)	RATE			
		<u> </u>	up to a whole humber)		¢		
47-100 =   /50 =   x \$250					\$		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).					\$		
CLAIMS NUMB		ER FILED	NUMBER EXTRA	RATE	\$		
Total claims		- 20 =		x \$ 50	\$	]	
Independent claims		- 3 =		x \$200	\$	<del> </del>	
MULTIPLE DEPENDENT CLAIM(S				+ \$360	\$	1	
TOTAL OF ABOVE CALCULATIONS =					\$		
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.							
SUBTOTAL =					\$ 1,000.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest					\$		
claimed priority date (37 CFR 1.492(i)). +					\$		
TOTAL NATIONAL FEE =					\$ 1,000.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$		
						<del></del>	
TOTAL FEES ENCLOSED =					\$ 1,000.00		
·					Amount to be refunded:	\$	
					Amount to be	\$	
					charged:	<u>I</u>	
a. A check in the amount of \$ to cover the above fees is enclosed.							
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees.  A duplicate copy of this sheet is enclosed.							
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0036. A duplicate copy of this sheet is enclosed.							
d. X Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not							
be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
SEND ALL CORRESPONDENCE TO:							
CUSTOME	R NUMBER		•				
					eresa A. Colella		
NAME							
REGISTRATIO					51,575		
REGISTRATIC					NI NUMBER		

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MENNE et al.

Appl. No.: To be assigned (U.S. Nat'l Phase of

PCT/DE2003/003165)

Filed: Herewith (I.A. Filing Date: September 23,

2003)

For: Inhibition of Protein Kinase C Alpha for Treatment of Diabetes Mellitus and

Cardiovascular Diseases

Confirmation No.: To be assigned

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 2376.0010000/SRL/TAC

## Authorization to Treat a Reply as Incorporating an Extension of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Teresa A. Colella Agent for Applicants Registration No. 51,575

Date: March 23, 2004

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

377590-1